Tony J. Hunt has been appointed chief executive officer of Repligen Corp. Mr. Hunt, currently Repligen’s chief operating officer, succeeds Walter C. Herlihy, Ph.D., who will retire in May 2015.
 
“Under Walter’s leadership, Repligen has been transformed from a therapeutics company that produced bioprocessing products into a focused bioprocessing industry leader, providing high-value consumable products for biological manufacturers and creating substantial value for our stockholders,” said Karen A. Dawes, chair of the board of Repligen. “Walter has been a major force in building this outstanding company, and the Board and I, on behalf of the stockholders, thank Walter for his dedication, vision, and leadership.”
 
Ms. Dawes continued, “We are delighted to promote Tony Hunt, a seasoned and successful bioprocessing industry executive as CEO. Tony joined Repligen in the spring of 2014 as chief operating officer and has quickly made a very positive impact as a leader by expanding our commercial footprint and effectively integrating our acquisition of Refine Technologies into our operations.”
 
Prior to joining the company, Mr. Hunt was president, BioProduction at Life Technologies, a global life sciences company acquired by Thermo Fisher Scientific in February 2014. Mr. Hunt also served as general manager Bioproduction Chromatography and Pharma Analytics and played a key role in the development and growth of the company’s bioprocessing business. Prior to that, he held positions at Applied Biosystems.